Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Unlabelled: Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) blockade (n = 53) followed by programmed death-1 (PD-1) blockade at progression (n = 46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified.

Significance: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types. Cancer Discov; 6(8); 827-37. ©2016 AACR.See related commentary by Teng et al., p. 818This article is highlighted in the In This Issue feature, p. 803.

Citing Articles

Analyze the Diversity and Function of Immune Cells in the Tumor Microenvironment From the Perspective of Single-Cell RNA Sequencing.

Ma L, Luan Y, Lu L Cancer Med. 2025; 14(5):e70622.

PMID: 40062730 PMC: 11891933. DOI: 10.1002/cam4.70622.

Multi-omics clustering analysis carries out the molecular-specific subtypes of thyroid carcinoma: implicating for the precise treatment strategies.

Wang Z, Han Q, Hu X, Wang X, Sun R, Huang S Genes Immun. 2025; .

PMID: 40038532 DOI: 10.1038/s41435-025-00322-w.

Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer.

Shi W, Bao X, Xiong J, Wu Y, Sun J, Xu Z Clin Exp Med. 2025; 25(1):71.

PMID: 40038111 PMC: 11880126. DOI: 10.1007/s10238-025-01606-1.

Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis.

Moussa M, Kovalenko I, Crupi E, Proskuriakova E, Geng Y, Fallara G Bladder Cancer. 2025; 10(4):300-312.

PMID: 40035076 PMC: 11864237. DOI: 10.1177/23523735241296763.

A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma.

Liu J, Yao L, Yang Y, Ma J, You R, Yu Z J Transl Med. 2025; 23(1):238.

PMID: 40016772 PMC: 11869577. DOI: 10.1186/s12967-025-06251-6.

References

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Huang R, Jalil J, Economou J, Chmielowski B, Koya R, Mok S . CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011; 17(12):4101-9. PMC: 3117971. DOI: 10.1158/1078-0432.CCR-11-0407. View

Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas K . Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2014; 2(2):127-32. PMC: 3991109. DOI: 10.1158/2326-6066.CIR-13-0163. View

OConnor C, Sheppard S, Hartline C, Huls H, Johnson M, Palla S . Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2:249. PMC: 3278154. DOI: 10.1038/srep00249. View

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

10.

Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A . VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015; 212(2):139-48. PMC: 4322048. DOI: 10.1084/jem.20140559. View

11.

Waggott D, Chu K, Yin S, Wouters B, Liu F, Boutros P . NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012; 28(11):1546-8. PMC: 3356845. DOI: 10.1093/bioinformatics/bts188. View

12.

Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D . Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17. PMC: 5744258. DOI: 10.1056/NEJMoa1414428. View

13.

Ohm J, Gabrilovich D, Sempowski G, Kisseleva E, Parman K, Nadaf S . VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003; 101(12):4878-86. DOI: 10.1182/blood-2002-07-1956. View

14.

Schadendorf D, Hodi F, Robert C, Weber J, Margolin K, Hamid O . Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33(17):1889-94. PMC: 5089162. DOI: 10.1200/JCO.2014.56.2736. View

15.

Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O . VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2012; 73(2):539-49. DOI: 10.1158/0008-5472.CAN-12-2325. View

16.

Shukla S, Rooney M, Rajasagi M, Tiao G, Dixon P, Lawrence M . Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015; 33(11):1152-8. PMC: 4747795. DOI: 10.1038/nbt.3344. View

17.

Das R, Verma R, Sznol M, Boddupalli C, Gettinger S, Kluger H . Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2014; 194(3):950-9. PMC: 4380504. DOI: 10.4049/jimmunol.1401686. View

18.

Ma W, Yang D, Gu Y, Guo X, Zhao W, Guo Z . Finding disease-specific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. Genomics. 2009; 94(2):94-100. DOI: 10.1016/j.ygeno.2009.05.001. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View